These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 17269924

  • 21. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H, Otaka A, Fujii N.
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L, Tong P, Chen YX, Hu ZW, Wang K, Zhang YN, Zhao DS, Cai LF, Liu KL, Zhao YF, Li YM.
    Org Biomol Chem; 2012 Aug 28; 10(32):6512-20. PubMed ID: 22760295
    [Abstract] [Full Text] [Related]

  • 25. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
    Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.
    Viruses; 2013 Jan 11; 5(1):127-49. PubMed ID: 23344560
    [Abstract] [Full Text] [Related]

  • 26. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
    Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E.
    J Virol; 2001 Sep 11; 75(18):8605-14. PubMed ID: 11507206
    [Abstract] [Full Text] [Related]

  • 27. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
    J Mol Biol; 2004 Jun 25; 340(1):9-14. PubMed ID: 15184018
    [Abstract] [Full Text] [Related]

  • 28. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
    Su S, Ma Z, Hua C, Li W, Lu L, Jiang S.
    Molecules; 2017 Nov 20; 22(11):. PubMed ID: 29156603
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
    Liu Y, Ke Z, Wu KY, Liu S, Chen WH, Jiang S, Jiang ZH.
    ChemMedChem; 2011 Sep 05; 6(9):1654-64. PubMed ID: 21688394
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
    Liu D, Wang H, Yamamoto M, Song J, Zhang R, Du Q, Kawaguchi Y, Inoue JI, Matsuda Z.
    Retrovirology; 2018 Apr 02; 15(1):27. PubMed ID: 29609648
    [Abstract] [Full Text] [Related]

  • 34. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB, Egelhofer M, von Laer D.
    J Virol; 2006 Apr 02; 80(7):3249-58. PubMed ID: 16537592
    [Abstract] [Full Text] [Related]

  • 35. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.
    Hermann FG, Egerer L, Brauer F, Gerum C, Schwalbe H, Dietrich U, von Laer D.
    J Virol; 2009 May 02; 83(10):4844-53. PubMed ID: 19279116
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.
    McGee TD, Yi HA, Allen WJ, Jacobs A, Rizzo RC.
    Bioorg Med Chem Lett; 2017 Jul 15; 27(14):3177-3184. PubMed ID: 28558972
    [Abstract] [Full Text] [Related]

  • 38. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
    Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S.
    J Biol Chem; 2007 Mar 30; 282(13):9612-9620. PubMed ID: 17276993
    [Abstract] [Full Text] [Related]

  • 39. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
    Chong H, Yao X, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, Cui S, He Y.
    J Biol Chem; 2012 Jun 08; 287(24):20281-9. PubMed ID: 22511760
    [Abstract] [Full Text] [Related]

  • 40. Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins.
    Jurado S, Cano-Muñoz M, Morel B, Standoli S, Santarossa E, Moog C, Schmidt S, Laumond G, Cámara-Artigas A, Conejero-Lara F.
    J Mol Biol; 2019 Aug 09; 431(17):3091-3106. PubMed ID: 31255705
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.